PCPaula R. Clemens

Paula R. Clemens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paula R. Clemens has a total of 261 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Muscle function, linear growth, and bone health during 30 months of vamorolone, prednisone, and deflazacort treatment for Duchenne muscular dystrophy: a comparative study

    by Leanne M Ward, Stefan Jackowski, Utkarsh J Dang, Maya Scharke B Comm, Jacob L Jaremko, Khaldoun Koujok, Mary-Ann Matzinger, Nazih Shenouda, Hugh J McMillan, Kerry Siminoski, et al.

    Corticosteroids are standard of care to slow disease progression in Duchenne muscular dystrophy (DMD) despite impaired growth and increased fracture risk. Vamorolone, a dissociative corticosteroid approved for DMD, showed stable growth and serum bone turnover markers in the 48-week VISION-DMD study. We compared muscle function and bone health from the non-randomized, open-label, 30-month Phase 2a VBP15-002/003/LTE trials (NCT02760264/NCT02760277/NCT03038399) in treatment-naive boys with DMD, aged 4 to 0.05). Thirty-month height z-scores remained stable from baseline for vamorolone (N=36; +0.078 least-squares-mean change) and decreased from baseline for prednisone (N=27, –0.668; change versus vamorolone: p<0.0001 mixed models for repeat measures) and deflazacort (N=28, –0.928; change versus vamorolone: p<0.0001). VF prevalence on vamorolone (8 VF in 5/39 boys [12.8%]) was ~50% lower than prednisone (13 VF in 7/27 boys [25.9%]) and deflazacort (19 VF in 8/28 boys [28.6%]). Compared with prednisone and deflazacort, vamorolone demonstrated similar motor function efficacy with significantly fewer VF and preserved growth.


  • Vamorolone for Duchenne Muscular Dystrophy

    by Paula R. Clemens, Anders Berglund, Marianela Schiava, Meredith K. James, Michael P. McDermott, Katherine Bushby, Erik Lampa, Edward Thomas James Rochford, Leanne M. Ward, Robert C. Griggs, et al.

  • Open Access

    Vamorolone for Duchenne Muscular Dystrophy

    by Paula R. Clemens, Anders Berglund, Marianela Schiava, Meredith K. James, Michael P. McDermott, Katherine Bushby, Erik Lampa, Edward Thomas James Rochford, Leanne M. Ward, Robert C. Griggs, et al.

    Vamorolone demonstrated similar efficacy for Duchenne muscular dystrophy (DMD) compared with prednisone in a 24-week exploratory analysis and may reduce key side effects compared with classic corticosteroids. In this study, we compare the efficacy and anthropometric effect of vamorolone 6 mg/kg/d with prednisone 0.75 mg/kg/d and deflazacort 0.9 mg/kg/d in steroid-naïve boys aged 4 to Z-scores increased in all groups, greatest with vamorolone (12-month LSM difference [95% CI]: vamorolone vs prednisone 0.57 [0.24-0.90]; vamorolone vs deflazacort 0.29 [0.03-0.56]), whereas growth slowdown occurred in prednisone- and deflazacort-treated boys but not vamorolone (12-month LSM difference in height Z-scores [95% CI]: vamorolone vs prednisone 0.57 [0.24-0.90]; vamorolone vs deflazacort 0.72 [0.53-0.91]). Vamorolone demonstrated numerically similar TTSTAND velocity changes to prednisone and deflazacort at 1 year; however, interpretations of differences are limited by 95% CIs crossing minimally important difference thresholds. Further evidence of the growth-protective effect of vamorolone was observed; however, all treatments increased BMI. Vamorolone provides a linear growth-protective classic corticosteroid alternative. NCT03439670; NCT01603407. This Class III study did not definitively identify differences in efficacy between vamorolone and classic corticosteroids but found that vamorolone protects linear growth in boys with DMD.


  • Open Access

    Test-Retest Reliability of Motor Function and Myometry Outcomes From the Vamorolone Trials in Duchenne Muscular Dystrophy

    by Rebecca A. Tobin, Eric P. Hoffman, Linda Johnson, Meredith K. James, Paula R. Clemens, Utkarsh J. Dang, the VBP15-LTE and VBP15-004 Investigators

    Understanding the reliability of outcomes used in clinical care and trials is important to delineate intervention-induced change from random variability. Reliability, sensitivity, and clinical meaningfulness of change are all key aspects of choosing the most appropriate outcome measure for a clinical trial. Common outcome measures to monitor progression and treatment effect in Duchenne muscular dystrophy (DMD) include measures of strength (myometry) and motor function tests: stand from supine velocity (STANDV), North Star Ambulatory Assessment (NSAA), 6-minute walk distance (6MWD), 10-m run/walk (RWV), and 4-stair climb velocity (CLIMBV). Our objective was to present test-retest reliability of common outcome measures using pretreatment measurements and to provide insights into missing measurements. Data were used on outcome measures in steroid-naïve, 4 to <7 years participants with DMD in 2 multisite, multicountry vamorolone trials (VBP15-002 [n = 48 participants] and VBP15-004 [n = 121 participants]). Bland-Altman analysis, the coefficient of variation, and the intraclass correlation coefficient (ICC) were used. Based on the ICC, NSAA, RWV, and CLIMBV have good reliability, whereas the 6MWD and STANDV have moderate reliability. Two different techniques were used for myometry in VBP15-002 (CINRG Quantitative Measurement System [CQMS]) and VBP15-004 (MicroFET2 handheld digital muscle dynamometer [HHD]). Reliability of myometry ranged from poor to moderate, and CQMS did not show improved reliability over HHD. The 6MWD and myometry showed the highest rates of missingness. Because of similar age ranges and harmonized outcomes, our findings were compared with the FOR-DMD cohort. Myometry and CLIMBV were not in FOR-DMD; reliability findings were concordant for the 4 outcomes in common. For most outcomes, we found reduced reliability compared with previous studies in older age groups. Reliable outcome measures, appropriate for the age of patients, are key to improving power in clinical trials, leading to fewer participants needed and reducing patient and site burden. We found NSAA, RWV, and CLIMBV to be the most reliable. This should be considered in the context of sensitivity to drug effect, and clinical meaningfulness of changes observed: all 5 motor outcomes were sensitive to drug effect of vamorolone and prednisone, whereas myometry was not.


  • Open Access

    Association of DMD Gene Variant Classes With Motor Outcomes in a Drug Registration Clinical Trial Setting

    by Yuan Fang, Utkarsh J. Dang, Katherine I. Illei, Paula Clemens, Eric P. Hoffman

    Duchenne muscular dystrophy (DMD) is caused by pathogenic variants of the DMD gene, leading to the loss of dystrophin. Clinical variability in DMD can complicate interpretation of interventional data in clinical trials. One source of clinical variability is allelic heterogeneity (different pathogenic variants with different effects on dystrophin protein expression). We sought to determine whether gene variant classes in clinical trial participants potentially affect clinical trial data interpretation. We analyzed 186 vamorolone trial participants with DMD (VBP15-002/003; VBP15-004) who were 4 to <7 years old and steroid-naïve at baseline. We stratified participants into gene variant classes by either variant location in the gene affecting different gene promoters (5′ [Dp427-only] vs 3′ [Dp427+other isoforms]) or residual dystrophin levels (null vs possible non-null [5′ gene variants, exon 44 skippable, splice site]). We evaluated associations with baseline motor outcomes and treatment response (prednisone and vamorolone). Participants with variants in ex63 and downstream (null for Dp427+Dp140+Dp71 protein isoforms) showed poorer baseline motor outcomes for time to stand from supine velocity than those with variants in ex1-44 (Dp427 only). No significant baseline differences were found between likely null and possible non-null variants. Participants with only Dp427 involvement showed significantly better treatment response for the 6-minute walk distance. Most of the comparisons of baseline motor function and treatment response were similar between variant classes. The large variation in baseline motor function in young, steroid-naïve patients with DMD is only minimally explained by different gene variant classes. While there is strong literature support for 3′ variants leading to a more severe motor and cognitive DMD phenotype, we found this variant class under-represented in our clinical trials. This suggests that they may fail inclusion criteria (failure to follow commands; poor motor function). Subgroup analyses in DMD clinical trials at a young age range based on gene variant class may not reveal significant differences and would be relatively noninformative.


  • Open Access

    Analysis of human urinary extracellular vesicles reveals disordered renal metabolism in myotonic dystrophy type 1

    by Preeti Kumari, Lauren M. Sullivan, Zhaozhi Li, E. Parker Conquest, Elizabeth Cornforth, Rojashree Jayakumar, Ningyan Hu, J. Alexander Sizemore, Brigham B. McKee, Robert R. Kitchen, et al.

    Chronic kidney disease (CKD) and the genetic disorder myotonic dystrophy type 1 (DM1) each are associated with progressive muscle wasting, whole-body insulin resistance, and impaired systemic metabolism. However, CKD is undocumented in DM1 and the molecular pathogenesis driving DM1 is unknown to involve the kidney. Here we use urinary extracellular vesicles (EVs), RNA sequencing, droplet digital PCR, and predictive modeling to identify downregulation of metabolism transcripts Phosphoenolpyruvate carboxykinase-1, 4-Hydroxyphenylpyruvate dioxygenase, Dihydropyrimidinase, Glutathione S-transferase alpha-1, Aminoacylase-1, and Electron transfer flavoprotein B in DM1. Expression of these genes localizes to the kidney, especially the proximal tubule, and correlates with muscle strength and function. In DM1 autopsy kidney tissue, characteristic ribonuclear inclusions are evident throughout the nephron. We show that urinary organic acids and acylglycines are elevated in DM1, and correspond to enzyme deficits of downregulated genes. Our study identifies a previously unrecognized site of DM1 molecular pathogenesis and highlights the potential of urinary EVs as biomarkers of renal and metabolic disturbance in these individuals.


  • Top Cited Papers

    First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy

    by Genís Prat-Ortega, Scott Ensel, Serena Donadio, Luigi Borda, Amy Boos, Prakarsh Yadav, Nikhil Verma, Jonathan Ho, Erick Carranza, Sarah Frazier-Kim, et al.

    Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease causing motoneuron dysfunction, muscle weakness, fatigue and early mortality. Three new therapies can slow disease progression, enabling people to survive albeit with lingering motor impairments. Indeed, weakness and fatigue are still among patients’ main concerns. Here we show that epidural spinal cord stimulation (SCS) improved motoneuron function, thereby increasing strength, endurance and gait quality, in three adults with type 3 SMA. Preclinical works demonstrated that SMA motoneurons show low firing rates because of a loss of excitatory input from primary sensory afferents. In the present study, we hypothesized that correcting this loss with electrical stimulation of the sensory afferents could improve motoneuron function. To test this hypothesis, we implanted three adults with SMA with epidural electrodes over the lumbosacral spinal cord, targeting sensory axons of the legs. We delivered SCS for 4 weeks, 2 h per day during motor tasks. Our intervention led to improvements in strength (up to +180%), gait quality (mean step length: +40%) and endurance (mean change in 6-minute walk test: +26 m), paralleled by increased motoneuron firing rates. These changes persisted even when SCS was turned OFF. Notably, no adverse events related to the stimulation were reported. ClinicalTrials.gov identifier: NCT05430113.


  • Open Access

    A Parent Project Muscular Dystrophy-sponsored International Workshop Report on Endocrine and Bone Issues in Patients with Duchenne Muscular Dystrophy: An Ever-changing Landscape

    by Leanne M Ward, David R Weber, Sze Choong Wong, Susan Apkon, Paula R Clemens, Linda H Cripe, Hugh J McMillan, Eugenio Mercuri, Nat Nasomyont, Kim Phung, et al.

    In April 2023, over 30 experts and advocates from four countries met in Rome, Italy to discuss unmet needs in endocrine and bone health care for individuals with Duchenne muscular dystrophy (DMD). Despite recent advances in muscle-targeted therapy, long-term glucocorticoids (GC) remain the backbone of treatment for the foreseeable future. This affirms the need to intensify efforts that will mitigate serious complications of GC therapy, including unexpected mortality due to fat embolism syndrome following bone injury and also unrecognized adrenal suppression, early loss of ambulation linked to excess weight and/or fragility fracture, adverse cardiometabolic effects of GC, the psychosocial impact of profound growth and pubertal delay/hypogonadism, and the burden to families arising from monitoring and treating endocrine and skeletal complications of GC therapy. Delegates discussed: 1. The impact of GC therapy on the heart, 2. Predictors of fragility fractures and experience with intravenous and oral bisphosphonates plus teriparatide, 3. The effect of hormonal therapy on muscle-bone health, 4. Adrenal suppression, 5. Weight management, 6. Puberty, sexuality, fertility and gender identity, 7. The impact of early GC initiation, 8. Emerging knowledge about vamorolone (a novel dissociative steroid) and its effects on muscle, bone and endocrine health, and 9. Experiences implementing an endocrine-bone health management strategy nation-wide (in the UK). At the conclusion of the meeting, it was agreed that an endocrine-bone working group should be struck to continue the narrative, following which the International OPTIMIZE DMD Consortium was ignited to move the dial in these important areas.


  • Open Access

    Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy

    by Amy D. Harper, Haluk Topaloglu, Eugenio Mercuri, Vasiliy Suslov, Liwen Wu, Cigdem Y. Ayanoglu, Michael Tansey, Michelle L. Previtera, Robert A. Crozier, Leslie Magnus, et al.

    Duchenne muscular dystrophy (DMD) is an X-linked recessive disease characterized by mutations in the dystrophin gene, causing motor and pulmonary function decline. Viltolarsen is indicated for patients with dystrophin gene mutations amenable to exon 53 skipping. Here, we report safety, motor function, and the first pulmonary function results from the open-label, phase II Galactic53 trial of viltolarsen (NCT04956289). Male participants aged ≥ 8 years with DMD received 80 mg/kg intravenous viltolarsen once weekly for 48 weeks. Results from participants receiving viltolarsen were compared with an external control cohort group-matched for multiple variables. All treatment-emergent adverse events were mild or moderate, 4 were considered treatment-related, and no participants discontinued. Participants receiving viltolarsen experienced clinically meaningful benefits in pulmonary function with higher percent predicted forced vital capacity and higher peak cough flow at Week 49 compared with the control cohort for both ambulatory and nonambulatory participants. Viltolarsen also stabilized upper limb motor function over the Treatment Period. These results support viltolarsen as an important part of the treatment armamentarium for both ambulatory as well as nonambulatory patients with DMD.


  • Open Access

    TARGETED STIMULATION OF THE SENSORY AFFERENTS IMPROVES MOTONEURON FUNCTION IN HUMANS WITH A DEGENERATIVE MOTONEURON DISEASE

    by G. Prat-Ortega, S. Ensel, S. Donadio, L. Borda, A. Boos, P. Yadav, N. Verma, J. Ho, S. Frazier-Kim, D.P. Fields, et al.

    SUMMARY: Spinal Muscular Atrophy (SMA) is an inherited neurodegenerative disease causing motoneuron dysfunction, muscle weakness and early mortality 1,2 . Three therapies can slow disease progression enabling people to survive albeit with lingering motoneuron dysfunction and severe motor impairments 3,4 . Here we introduce a neurotechnological approach that improved spinal motoneuron function, muscle strength and walking in three adults with SMA. Starting from preclinical evidence showing that motoneuron dysfunction in SMA originates from the loss of excitatory inputs from primary afferents 5,6 , we hypothesized that augmentation of sensory neural activity with targeted electrical stimulation could compensate for this loss thereby improving motoneuron function. To test this hypothesis we implanted three adults with SMA with epidural electrodes over the lumbosacral spinal cord to stimulate the sensory axons of the legs 7,8 . We stimulated participants for 4 weeks 2 hours per day while they executed walking and strength tasks. Remarkably, our neurostimulation regime led to robust improvements in strength, walking and fatigue paralleled by reduced neuronal hyperexcitability, increased sensory inputs and higher motoneuron firing rates. Our data indicate that targeted neurostimulation can reverse degenerative processes of circuit dysfunction thus promoting disease modifying effects in a human neurodegenerative disease.